Compare Merck & Co., Inc. (MRK) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Star Bulk Carriers Corp — how do they compare? Merck & Co., Inc. trades at $132.68 (market cap $321.77B), while Star Bulk Carriers Corp trades at $27.91 (market cap $3.09B). The key difference: Merck & Co., Inc. is far larger — about 104.1× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.79%). Which is the better fit depends on your goals.
| MRK | SBLK | |
|---|---|---|
Market Cap | $321.77B | $3.09B |
Sector | Health | Industrials |
52-Week High | $132.93 | $29.15 |
52-Week Low | $77.60 | $16.79 |
Enterprise Value | $368.53B | $3.77B |
Dividend Yield | 2.61% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, net income was $18.25B, and the P/E ratio stands at 104.34. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook: Merck's acquisition strategy and consistent dividend payments ($0.85 per share) support a positive view, with analyst consensus price target at $140.58. Risks include high valuation multiples and competitive pressures in pharmaceuticals. Institutional holdings show increased interest, but investors should monitor integration of acquisitions and patent expirations.
Star Bulk Carriers (SBLK) trades at $27.89, down 1.86% on the day, amid a bullish technical signal and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Valuation metrics appear attractive with a P/E of 10.85 and EV/EBITDA of 7.46, while profitability improved significantly with a net margin of 23.87% in 2026. Recent news highlights dividend declarations and strong operational results.
Outlook remains positive driven by earnings beats and healthy cash flow, though risks include dry bulk rate volatility and competitive pressures. Analyst consensus is bullish with 14 buy ratings, supporting potential upside, but investors should monitor shipping market cycles and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
